Loading...
XWAR
CRM
Market cap8mUSD
Dec 05, Last price  
0.39PLN
1D
-0.52%
1Q
-22.65%
Jan 2017
-81.44%
IPO
-90.47%
Name

PZ Cormay SA

Chart & Performance

D1W1MN
XWAR:CRM chart
P/E
—
P/S
0.35
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
6.02%
Revenues
92m
+11.43%
31,085,00038,451,00061,940,00090,027,000105,473,000100,800,000100,111,00045,004,00082,277,00077,585,00069,793,00068,410,00065,290,00084,732,00085,361,00082,225,00091,623,000
Net income
-5m
L+17.15%
1,420,0002,956,0006,130,00014,008,00015,382,0006,853,000-47,357,000-5,157,000-10,990,000-2,021,000-24,982,000-40,974,000-12,821,0001,635,000-6,644,000-4,496,000-5,267,000
CFO
-3m
L+0.22%
2,203,000-1,582,000-9,747,0002,334,0002,254,000-17,451,0007,928,000-5,271,000-5,167,0001,656,000-1,561,000-4,390,000-161,000-1,469,000-8,709,000-3,249,000-3,256,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PZ Cormay S.A. develops, manufactures, and sells diagnostic reagents in Poland. It offers testing products for clinical chemistry, hematology, veterinary, urinalysis, and parasitology, as well as rapid test products. The company serves small and medium size clinical laboratories, clinics, and hospitals. It distributes its products to approximately 120 countries. PZ Cormay S.A. was founded in 1985 and is headquartered in Lomianki, Poland.
URL
https://cormay.com/
IPO date
Aug 20, 2008
Employees
222
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT